Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S reported that the US FDA has accepted a Supplemental New Drug Application for the treatment of schizophrenia in adolescents with Rexulti^® and has granted Otsuka and Lundbeck Priority Review.